Moleculin Biotech, Inc. (MBRX) fundamentals score
Moleculin Biotech is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name “naxtarubicin”, which it believes is a “next-generation” anthracycline and, with it, are conducting a pivotal Phase 3 trial in combination with cytarabine for the treatment of subjects with relapsed/refractory (R/R) acute myeloid leukemia (AML).
Pharmaceutical Preparations · Healthcare · Listed on NASDAQ
Overall: 3.1 out of 10, Unhealthy fundamentals
- Growth: 3.5/10
- Profitability: 1.0/10
- Financial health: 4.8/10
- Earnings quality: 5.5/10
- Valuation: 1.5/10
Scores are calculated from Moleculin Biotech, Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10